Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Satraplatin (BMS182751) 是一种烷化剂 ,是一种口服的抗肿瘤铂 (IV) 复合物,具有广泛的抗肿瘤效果。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,160 | 现货 | ||
5 mg | ¥ 2,710 | 现货 | ||
10 mg | ¥ 3,930 | 现货 | ||
25 mg | ¥ 6,290 | 现货 | ||
50 mg | ¥ 8,660 | 现货 | ||
100 mg | ¥ 11,600 | 现货 |
产品描述 | Satraplatin (BMS182751) is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies. |
体外活性 | KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells[1]. |
细胞实验 | CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment[1]. |
别名 | BMS182751, JM216, 顺式-二氯-反式-二乙酸-氨-环己胺合铂, BMY45594 |
分子量 | 500.28 |
分子式 | C10H22Cl2N2O4Pt |
CAS No. | 129580-63-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33 mg/mL (65.96 mM), DMSO inactivates the activity of Satraplatin.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9989 mL | 9.9944 mL | 19.9888 mL | 49.972 mL |
5 mM | 0.3998 mL | 1.9989 mL | 3.9978 mL | 9.9944 mL | |
10 mM | 0.1999 mL | 0.9994 mL | 1.9989 mL | 4.9972 mL | |
20 mM | 0.0999 mL | 0.4997 mL | 0.9994 mL | 2.4986 mL | |
50 mM | 0.04 mL | 0.1999 mL | 0.3998 mL | 0.9994 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Satraplatin 129580-63-8 DNA Damage/DNA Repair DNA Alkylator/Crosslinker DNA Alkylation BMS 182751 BMY-45594 BMS182751 JM216 BMS-182751 BMY 45594 JM 216 Inhibitor inhibit 顺式-二氯-反式-二乙酸-氨-环己胺合铂 BMY45594 JM-216 inhibitor